Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827462 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL1985823 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL2175496 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL2176899 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL2177991 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL2174526 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL132521 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL2173439 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL536857 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 | |
| SCHEMBL294141 | 1.00 | LMNA (0.43) | LMNAKDM4CTRPV1KDM4APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 761 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106456588-B | Methods for the microbial production of capsaicinoids using capsaicin synthase | 科纳根公司 | 2021-04-30 | — | — | CN | claimed |
| US-10711040-B2 | Low substituted polymyxins and compositions thereof | XELLIA PHARMACEUTICALS APS (DK) | 2020-07-14 | — | — | US | claimed |
| US-10640536-B2 | Polymyxins, compositions, methods of making and methods of use | XELLIA PHARMACEUTICALS APS (DK) | 2020-05-05 | — | — | US | claimed |
| EP-3166960-B1 | LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF | XELLIA PHARMACEUTICALS APS (DK) | 2019-08-07 | — | — | EP | claimed |
| EP-2946795-B1 | TISSUE ADHESIVE AND PROCESS FOR PRODUCING SAME | NAT INST MATERIALS SCIENCE (JP) | 2019-04-17 | — | — | EP | claimed |
| US-10064973-B2 | Tissue adhesive and method for producing same | NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) | 2018-09-04 | — | — | US | claimed |
| EP-3109254-B1 | CROSSLINKED NUCLEOSIDE AND NUCLEOTIDE | UNIV OSAKA (JP) | 2018-04-11 | — | — | EP | claimed |
| EP-2943503-B1 | POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | XELLIA PHARMACEUTICALS APS (DK) | 2017-08-23 | — | — | EP | claimed |
| US-20170218024-A1 | LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF | XELLIA PHARMACEUTICALS APS (DK) | 2017-08-03 | — | — | US | claimed |
| EP-3166960-A1 | LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF | Xellia Pharmaceuticals ApS (DK) | 2017-05-17 | — | — | EP | claimed |
| US-5039789-A | Antibacterial agents | ELI LILLY AND COMPANY (US) | 1991-08-13 | — | — | US | claimed |
| US-5028590-A | Animal Growth Promoters | ELI LILLY AND COMPANY (US) | 1991-07-02 | — | — | US | claimed |
| US-4977083-A | Feeding alkanoic or alkenoic acids, esters, salts or alcohols to cultures of Streptomyces fradiae | ELI LILLY AND COMPANY (US) | 1990-12-11 | — | — | US | claimed |
| WO-1990011300-A1 | NEW SUBSTITUTED ALKYLAMIDE DERIVATIVES OF TEICOPLANIN | GRUPPO LEPETIT S.P.A. (IT) | 1990-10-04 | — | — | WO | claimed |
| CN-1043941-A | 34-takes off the C63 amide derivatives of (N-acetyl glucosamine amido)-34-deoxidation-teicoplanins | LEPETIT SPA (IT) | 1990-07-18 | — | — | CN | claimed |
| EP-0376041-A2 | C63-Amide derivatives of 34-de(acetylglucosaminyl)-34-deoxy-teicoplanins | GRUPPO LEPETIT S.p.A. (IT) | 1990-07-04 | — | — | EP | claimed |
| EP-0340245-A1 | SUBSTITUTED ALKYLAMIDES OF TEICOPLANIN COMPOUNDS. | LEPETIT SPA (IT) | 1989-11-08 | — | — | EP | claimed |
| EP-0337731-A2 | Peptide antibiotics | ELI LILLY AND COMPANY (US) | 1989-10-18 | — | — | EP | claimed |
| CN-88101000-A | The alkylamide of the replacement of teicoplanin compounds | — | 1988-09-14 | — | — | CN | claimed |
| WO-1988006600-A1 | SUBSTITUTED ALKYLAMIDES OF TEICOPLANIN COMPOUNDS | GRUPPO LEPETIT S.P.A. (IT) | 1988-09-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640536-B2 | Polymyxins, compositions, methods of making and methods of use | C5, HRH3, SGMS1 | LMNA 1993/4885KDM4C 1751/4885TRPV1 2910/4885 |
| US-20170218024-A1 | LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF | TLR3, TLR4, TLR5 | LMNA 1175/4885KDM4C 2406/4885TRPV1 1780/4885 |
| US-10711040-B2 | Low substituted polymyxins and compositions thereof | TLR3, TLR4, TLR5 | LMNA 1175/4885KDM4C 2406/4885TRPV1 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.